KR-102953536-B1 - Composition for skin regeneration and wrinkle improvement comprising liposomal ingredients containing encapsulated polylactic acid and PDRN with enhanced skin penetration as active ingredients

Abstract

The present invention relates to a cosmetic composition comprising a surfactant-dispersed poly-L-lactic acid complex (SDC-PLLA) encapsulated in cellulose derivatives and a liposome containing polydeoxyribonucleotide (PDRN) as active ingredients, and a method for preparing the same. The liposome component containing a micro SDC-PLLA complex encapsulated in ethyl cellulose and PDRN according to the present invention has no cytotoxicity, effectively penetrates skin cells even when administered in minute amounts at the ppm level, promotes cell regeneration to be effective for skin wound healing, and increases the expression of the COL1A1 gene to be effective for skin wrinkle improvement, so it can be usefully utilized in cosmetics or quasi-drugs for skin wound healing or wrinkle improvement.

Inventors

• 고서영
• 김지영
• 이승희
• 고병호
• 정성원
• 고은별
• 임태준
• 이아람
• 조상호
• 이성현
• 주영협
• 윤석민
• 방원정

Assignees

• (주)에스디생명공학
• 대원제약주식회사
• 주식회사 두래

Dates

Publication Date

20260507

Application Date

20250905

Claims (8)

1. A liposome containing a surfactant-dispersed poly-L-lactic acid complex (SDC-PLLA, Surfactant-Dispersed Poly-L-lactic acid Complex) encapsulated in cellulose derivatives; and PDRN (Polydeoxyribonucleotide) as an active ingredient, wherein The above cellulose derivatives are characterized by being one or more selected from ethylcellulose, methylcellulose, nitrocellulose, methylhydroxypropylcellulose, hydroxyethylcellulose, sodium cellulose sulfate, hydroxypropylcellulose, sodium carboxymethylcellulose (CMC), and crystalline cellulose. The above surfactant-dispersed PLLA complex (SDC-PLLA, Surfactant-Dispersed Poly-L-lactic acid Complex) is characterized by having a particle size of 40 to 300 nm, and The above liposome is characterized by simultaneously exhibiting skin wound regeneration promoting and wrinkle improvement activities. Cosmetic composition for improving skin condition.
2. delete
3. In paragraph 1, The above surfactant is characterized by being one or more selected from the group consisting of sorbitan stearate, sorbitan palmitate, sorbitan isostearate, sorbitan sesquistearate, sorbitan oleate, sorbitan sesquioleate, and sorbitan olivate. Cosmetic composition for improving skin condition.
4. In paragraph 1, The Polydispersity Index (PI) of the above surfactant-dispersed PLLA complex (SDC-PLLA, Surfactant-Dispersed Poly-L-lactic acid Complex) is 0.194, Cosmetic composition for improving skin condition.
5. In paragraph 1, The above liposome is characterized by further containing an adenosine component, Cosmetic composition for improving skin condition.
6. A liposome containing a surfactant-dispersed poly-L-lactic acid complex (SDC-PLLA, Surfactant-Dispersed Poly-L-lactic acid Complex) encapsulated in cellulose derivatives; and PDRN (Polydeoxyribonucleotide) as an active ingredient, wherein The above cellulose derivatives are characterized by being one or more selected from ethylcellulose, methylcellulose, nitrocellulose, methylhydroxypropylcellulose, hydroxyethylcellulose, sodium cellulose sulfate, hydroxypropylcellulose, sodium carboxymethylcellulose (CMC), and crystalline cellulose. The above surfactant-dispersed PLLA complex (SDC-PLLA, Surfactant-Dispersed Poly-L-lactic acid Complex) is characterized by having a particle size of 40 to 300 nm, and The above liposome is characterized by simultaneously exhibiting skin wound regeneration promoting and wrinkle improvement activities. Composition of a quasi-drug for improving skin condition.
7. A step of preparing a first solution (organic phase) by dissolving PLLA (Poly-L-lactic acid) and ethyl cellulose in an organic solvent; A step of preparing a second solution (aqueous phase) by dissolving sorbitan stearate and 1,2-hexanediol in purified water; A step of preparing a surfactant-dispersed poly-L-lactic acid complex (SDC-PLLA, Surfactant-Dispersed Poly-L-lactic acid Complex) encapsulated in ethyl cellulose by adding the first solution to the second solution and stirring sufficiently, and then evaporating the solvent; A step of preparing a lecithin solution by mixing hydrogenated lecithin and glycerin in purified water and dissolving them for 30 minutes under conditions of 70–80°C and 500–1,000 rpm; A step of preparing a mixed solution by adding the surfactant-dispersed PLLA complex (SDC-PLLA, Surfactant-Dispersed Poly-L-lactic acid Complex) encapsulated in ethyl cellulose and PDRN components to the lecithin solution, and stirring for 10 to 30 minutes at 500 to 1,000 rpm; and A step comprising: adding squalane to the above mixed solution and then emulsifying under conditions of 10,000 to 20,000 psi (pressure) to produce liposomes; A method for preparing a liposome containing a surfactant-dispersed poly-l-lactic acid complex (SDC-PLLA, Surfactant-Dispersed Poly-L-lactic acid Complex) encapsulated in cellulose derivatives; and PDRN (Polydeoxyribonucleotide).
8. In Paragraph 7, A method for preparing a liposome containing a surfactant-dispersed poly-L-lactic acid complex (SDC-PLLA, Surfactant-Dispersed Poly-L-lactic acid Complex) encapsulated in cellulose derivatives; and PDRN (Polydeoxyribonucleotide), characterized by adding adenosine further to the step of preparing the above-mentioned mixed solution to prepare a mixed solution containing adenosine.

Description

Composition for skin regeneration and wrinkle improvement comprising liposomal ingredients containing encapsulated polylactic acid and PDRN with enhanced skin penetration as active ingredients The present invention relates to a composition for skin regeneration and wrinkle improvement that simultaneously exhibits skin wound regeneration promotion and wrinkle improvement activity and has improved skin penetration power. More specifically, it relates to a cosmetic or quasi-drug composition comprising a liposome component containing a surfactant-dispersed poly-L-lactic acid (PLLA) complex encapsulated in a cellulose derivative and PDRN as active ingredients. Skin aging or damage is caused by various exogenous and endogenous factors, such as ultraviolet radiation, reactive oxygen species, inflammatory signals, mechanical irritation, and dryness. As a result, reduced collagen synthesis and accelerated degradation occur, leading to a deterioration of skin conditions including wrinkle formation, loss of elasticity, and delayed wound healing. To address these issues, it is necessary to achieve a combination of extracellular matrix (ECM) remodeling, inflammation alleviation, fibroblast activation, and the restoration of epidermal and dermal homeostasis. In this regard, poly-L-lactic acid (PLLA) is a biodegradable polymer that is hydrolyzed into lactic acid in the body and is known to promote neocollagenesis (induction of new collagen) in the medical and cosmetic fields, and has been applied in various formulations. However, since PLLA is inherently hydrophobic and insoluble in aqueous phases, it is difficult to ensure dispersion stability in cosmetic formulations. In particular, problems such as particle aggregation and sedimentation, a wide particle size distribution (increase in PDI), and size increase during long-term storage are frequently reported in aqueous environments, in the presence of salts, or under the addition of preservatives and fragrances. To improve this, physical processes such as dispersion using surfactants like sorbitan-based ones, solvent exchange (nano-precipitation), emulsification-solvent evaporation, or ultra-high pressure homogenization (HPH) have been proposed; however, practical limitations still exist regarding long-term storage stability, stabilization under low-concentration surfactant conditions, and improvement of skin applicability (adhesion and whiteness). Meanwhile, cellulose derivatives are known as representative polymer adjuvants utilized for controlling formulation viscosity, film formation, and release, as well as stabilizing particle surfaces. Particle encapsulation using these derivatives offers advantages such as inhibiting aggregation in the aqueous phase and providing stability against external stimuli (temperature and ionic strength); however, depending on the type, molecular weight, degree of substitution, and compatibility with surfactants of the derivative, challenges may arise, including reduced processability due to increased viscosity, non-uniform dispersion, and degradation of sensory properties (spreadability and absorption). Furthermore, when the polymer membrane used for encapsulation is thick, delayed release of active ingredients or reduced penetration efficiency have been identified as issues. Furthermore, PDRN (Polydeoxyribonucleotide), a nucleic acid-based active ingredient, has garnered attention for its tissue regeneration-promoting and anti-inflammatory effects, leading to research on delivery systems such as liposomes and nanoemulsions aimed at healing skin wounds and improving their condition. However, liposomes are sensitive to composition (phospholipid-to-cholesterol ratio), particle size, charge (ζ-potential), and surfactant environments, resulting in frequent stability issues such as leakage, fusion/aggregation, and size increase during long-term storage. Moreover, when PLLA dispersions—other polymers or nanoparticles—coexist within or on the surface of liposomes, electrostatic and hydrophobic interactions can easily lead to reduced compatibility, phase separation, and increased turbidity, which impair the sensory quality of the formulation and the delivery efficiency of the active ingredient. In conventional technology, the mainstream approach has been to use PLLA dispersions alone to induce wrinkle improvement or collagen regeneration, or to use PDRN liposomes alone to expect wound healing and anti-inflammation. Additionally, there have been attempts to assist in wrinkle improvement by adding functional ingredients such as adenosine, but it has been difficult to simultaneously satisfy industrial requirements such as physical stability in multi-component, multi-particle systems, maintenance of narrow distribution (low PDI), stability under low surfactant dosage, and compatibility with skin applicability. In particular, when PLLA dispersions (nano/microparticles) and PDRN liposomes coexist in the same formulation, problems such as re-aggregatio